Company Description
Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases.
The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases.
It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea.
The company was founded in 2019 and is headquartered in Warren, New Jersey. On November 17, 2023, Timber Pharmaceuticals, Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
Contact Details
Address: 3 Mountainview Road, Suite 100 Warren, New Jersey 07059 United States | |
| Phone | (917) 697-3130 |
Stock Details
| Ticker Symbol | TMBRQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001504167 |
| Employer ID | 59-3843182 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John Koconis M.B.A. | Chairman, Chief Executive Officer and President |
| Joseph Lucchese | Executive Vice President, Chief Financial Officer, Treasurer and Secretary |
| Dr. Alan Mendelsohn M.D. | Executive Vice President and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2024 | 8-K | Current Report |
| Feb 22, 2024 | 8-K | Current Report |
| Jan 26, 2024 | 8-K | Current Report |
| Jan 23, 2024 | 8-K | Current Report |
| Dec 22, 2023 | 8-K | Current Report |
| Nov 29, 2023 | 25-NSE | Filing |
| Nov 28, 2023 | 8-K | Current Report |
| Nov 17, 2023 | 8-K | Current Report |
| Nov 17, 2023 | 8-K | Current Report |
| Nov 15, 2023 | NT 10-Q | Notification of inability to timely file Form 10-Q or 10-QSB |